Jubilant Pharmova Limited has informed the Exchange about Resignation of Director/KMP/SMP
JUBLPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.0 pts less than Nifty Smallcap 250 and 0.6 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Jubilant Pharmova's Chief Financial Officer, Mr. Arun Kumar Sharma, has resigned effective close of business hours on May 22, 2026. He will transition to a new role as Advisor to the Chairmen. Simultaneously, the company appointed Mr. Ashish Mukkirwar as the new CFO and Key Managerial Personnel effective May 23, 2026. Mukkirwar joins from Glenmark Pharmaceuticals where he served as Group Vice President & CFO - Global Formulations Business, bringing over two decades of experience in corporate finance, M&A, and investor relations. The board meeting where this was approved commenced at 11:30 AM and concluded at 2:10 PM on May 22, 2026.
The CFO transition appears orderly with the outgoing CFO moving to an advisory role rather than leaving entirely, which may reduce market concern. However, investors should monitor the new CFO's initial communications and quarterly results for signs of any strategic shifts.